G0S2 mRNA was substantially downregulated in both imatinib non‐responders who lack kinase domain mutations (GSE14671, Figure S1A),12, 35 and in BP‐CML versus CP‐CML patients in another study (E‐MEXP‐480, Figure S1B).36 Here, G0S2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.